Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) CEO Jason Carrol joins Jonathan Jackson in the Proactive studio to discuss promising results from a Phase 2a clinical trial in collaboration with the University of Michigan (UOM).

The trial focused on TRP-8802, Tryp's oral psilocybin formulation, administered with psychotherapy to patients suffering from fibromyalgia. All participants reported improvements in pain severity, sleep, pain interference and other quality-of-life measures one month post-dosing. Notably, there was a clinically meaningful reduction in pain, pain interference and fatigue. Additionally, four out of five patients experienced reduced anxiety and improved cognitive abilities, with one patient reporting the return of their sense of smell after losing it due to a COVID-19 diagnosis in 2021.

The results were presented at the International Association for the Study of Pain (IASP) 2024 World Congress in the Netherlands.

Carroll emphasised the significance of these findings in potentially offering a more effective treatment pathway for fibromyalgia compared to existing options. The company is now planning a future Phase 2 trial using TRP-8803, with the trial expected to commence in H1 2025. Additional trials are ongoing at MGH for IBS patients, and further updates will be provided.